Rival GW Pharmaceuticals came out the big winner, as its competing seizure drug looks more effective.
News & Analysis: Zogenix
Despite reports of positive late-stage results for an important drug candidate, Wall Street was hoping for more.
ZGNX earnings call for the period ending September 30, 2019.
Surprisingly, it had nothing to do with the pharma company's earnings report.
One of these stocks continued to see fallout from recent executive moves.
The biotech is making an acquisition deal that investors don't appear to approve of.
ZGNX earnings call for the period ending June 30, 2019.
The company rebounded after remedying an embarrassing regulatory gaffe.
The company cleared up an issue with the FDA.
ZGNX earnings call for the period ending March 31, 2019.